Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013
Methods: Annual cross-sectional seroprevalence surveys of PWID entering a large drug abuse treatment program in NYC. Risk behavior questionnaires were administered, and HIV and HCV testing were conducted. Comparisons were made with prior prevalence data and incidence estimates in 1990-91 and 2000-01 reflecting different periods of combined prevention and treatment efforts.
Results: HCV prevalence among PWID (N: 1,535) was 67% (95% CI: 66-70%) during the study period, and was not significantly different from that observed in 2000-2001. The estimated HCV incidence among new injectors (persons injecting for up to 6 years) during 2006-2013 was 19.5/100 PYO (95% CI: 17-23) and did not differ from the estimated incidence among new injectors in 2000-2001 of 18/100 PYO (95% CI: 14-23/100). There was no significant difference in the estimated annual HCV incidence in each year of study period.
Conclusions: During the study period in which combined prevention programming was associated with a significant decrease in HIV prevalence, HCV prevalence remained high. The estimated HCV incidence among new injectors also remained high, and was not significantly lower than in 2000-2001, indicating that expanded combined prevention efforts are urgently needed to control the HCV epidemic among PWID in NYC.
Public health or related research
Describe the prevalence of hepatitis C virus among different groups of people who use drugs in New York City. Identify trends in the prevalence of hepatitis C virus among people who use drugs in New York City.
Keyword(s): Hepatitis C, Drug Abuse
Qualified on the content I am responsible for because: I am a public health Doctoral student in epidemiology and a public health researcher with almost 10 years of research and direct service experience with people who inject drugs and the prevention and treatment of injection-related infections.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.